NYSE Content Update: Defense Tech Company AEVEX to Make Its Public Debut
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, April 17, 2026 /PRNewswire/ -- The New York...
immunotherapy
Immuron Double Digit 3Q Sales Growth
Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million...
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44%...
ELEPHAS BIOSCIENCES AND MITHRL PAIR REAL-TIME TUMOR PROFILING WITH AGENTIC AI TO UNLOCK NEW IMMUNOTHERAPY RESPONSE INSIGHTS
Data abstract from this collaboration accepted for presentation at the American Association for Cancer Research Annual Meeting 2026MADISON, Wis., April...
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage...
RBL LLC launches Duracyte, advancing living pharmacy platform in Houston’s growing biotech hub
Duracyte is a biotechnology company developing implantable "living pharmacy" devices designed to continuously produce therapeutic proteins inside the bodyThe company...
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel...
Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers
Er-Kim announces exclusive partnership with LEO Pharma A/S to launch LOQTORZI® across Central and Eastern Europe, expanding access to innovative...
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage...
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead...
Trained Therapeutix Discovery’s Chief Scientific Officer, Dr. Mulder, Honored with Fellowship at the American Institute for Medical and Biological Engineering (AIMBE)
-Recognition highlights pioneering contributions to nanomedicine underpinning the company’s RIDE platformOSS, The Netherlands, April 14, 2026 (GLOBE NEWSWIRE) -- Trained...
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology...
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated...
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement...
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and...
Cures Within Reach Approves Five Clinical Trials at Chicago-based Research Institutions
Clinical trials are led by early-stage investigators and/or impact health equity, veterans and pediatricsFuture funding increased to offset cuts in...
Precision Nanomedicine to Target the Most Challenging Tumors
ISS National Lab‑enabled research supports next‑generation chemotherapy and immunotherapy developmentKENNEDY SPACE CENTER, Fla., April 9, 2026 /PRNewswire/ -- Eascra Biotech...
Over 60 Million Showed They Are #MoreThanMyeloma During 2026 Myeloma Action Month
Myeloma Action Month Global Campaign Celebrated Resilience, Strengthened Connections, and Inspired Hope in 96 CountriesSTUDIO CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- As this year’s...
Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 8, 2026 /PRNewswire/ -- Caris...
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares
Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company...